Opaldia to Offer DiaGenic's Gene Expression Tests in UK | GenomeWeb
NEW YORK (GenomeWeb News) – Opaldia will distribute DiaGenic’s breast cancer blood test in the UK and will use a research-use-only version of the test in its own studies until the test receives the CE Mark for use in Europe.
Opaldia will offer the gene expression test to UK patients under its Breastcare Program. The firm already offers Agendia’s MammaPrint, which is used in disease prognosis, and Agendia's CupPrint, which identifies the origin of metastasized tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.